Top Stories
Gilead pays $3.1B upfront for Tubulis in ADC land grab
Gilead Sciences struck a $5 billion deal to acquire German biotech Tubulis, paying $3.15 billion upfront with up to $1.85 billion in milestones, according to Fierce Biotech. The acquisition secures an antibody-drug conjugate candidate racing toward pivotal trials in ovarian cancer. BioPharma Dive reported this marks Gilead's third major acquisition since late February, signaling an aggressive M&A strategy to bolster its oncology pipeline. The deal marks Gilead's third acquisition since late February, following the $7.8 billion Arcellx buy and the $2 billion Ouro Medicines deal, signaling a sustained M&A push to rebuild its oncology pipeline. Tubulis brings proprietary linker technology that could differentiate its ADCs from the crowded field dominated by Daiichi Sankyo and AstraZeneca. The acquisition gives Gilead immediate access to late-stage ADC assets targeting solid tumors, positioning the company to compete directly with established ADC leaders. Gilead gains instant ADC credibility Smaller ADC biotechs face higher acquisition bar
MSD Secures EC Clearance for Keytruda Combination in Platinum-Resistant Ovarian Cancer
The European Commission approved MSD's Keytruda (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, for PD-L1-positive (CPS ≥1) platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal carcinoma on April 2, 2026, according to Pharmaceutical Technology. The approval, based on the phase III KEYNOTE-B96 (ENGOT-ov65) trial, makes Keytruda the first and only PD-1 inhibitor-based treatment approved in the EU for this indication. The trial demonstrated a 28% reduction in the risk of disease progression or death and a 24% reduction in the risk of death in the PD-L1 CPS ≥1 population. The decision follows a CHMP positive opinion issued in February 2026 and a corresponding FDA approval in February 2026 for the same regimen. The EC authorization covers all 27 EU member states plus Iceland, Liechtenstein, and Norway. Platinum-resistant ovarian cancer patients in the EU gain first immunotherapy-based option Existing chemotherapy-only regimens face competitive displacement in PD-L1-positive patients
CatalYm launches Phase 2b trial of visugromab in liver cancer
CatalYm initiated a Phase 2b trial of visugromab in second-line hepatocellular carcinoma, expanding development of the antibody into liver cancer treatment, according to PharmaTimes. The study represents a strategic move into the second-line HCC market for patients who progress after first-line anti-PD-(L)1 therapy, where tyrosine kinase inhibitors like lenvatinib remain the primary option. Visugromab targets GDF-15, an immunosuppressive cytokine exploited by tumor cells, potentially offering a novel approach to restoring immune sensitivity in IO-refractory liver cancer. The Phase 2b design suggests CatalYm is confident enough in early data to skip smaller proof-of-concept studies. Success in HCC could position visugromab as a significant player in the global liver cancer therapeutics market, estimated at $2.8 billion according to industry analyses. The trial timing coincides with increasing investor interest in novel HCC targets as existing treatments show limited overall survival benefits. CatalYm advances into high-value HCC indication Established HCC treatments face new competition
EMN24 IsKia trial tests four-drug combo in newly diagnosed myeloma
The randomized Phase 3 EMN24 IsKia trial evaluated isatuximab plus carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients, according to Nature Medicine. The four-drug combination represents an escalation in treatment intensity for transplant-eligible patients, challenging the current standard triplet regimens. Data from the trial could reshape first-line myeloma treatment if the combination shows superior progression-free survival without prohibitive toxicity. The study design targets the competitive landscape where Janssen's Darzalex dominates with multiple approved combinations. Isatuximab, Sanofi's competing CD38 antibody, has struggled to gain significant market share against Darzalex despite similar efficacy profiles. Results from EMN24 could provide the differentiation Sanofi needs to challenge Janssen's dominant position in the CD38 antibody market. The trial represents a critical inflection point for isatuximab's commercial trajectory in the multiple myeloma market, estimated at approximately $8 billion according to industry analyses. Four-drug combos gain clinical validation Standard triplet regimens face obsolescence risk
Pipeline Watch
Stipple Bio emerged from stealth with $100 million in funding to develop more precise cancer protein targets, per Endpoints News. The company's Pointillist Platform identifies tumor-specific cell surface epitopes to develop precision therapies with improved therapeutic index, potentially unlocking targets previously intractable with conventional antibody approaches.
Stichting Hemato-Oncologie is recruiting patients for a bleximenib combination trial in acute myeloid leukemia, per ClinicalTrials.gov (NCT07223814). The study combines bleximenib with standard induction and consolidation therapy followed by maintenance, targeting the challenging AML patient population where novel approaches are desperately needed.
ASCO published updated guidelines for managing thyroid cancer in 2026, according to CancerNetwork. The guideline updates reflect evolving treatment paradigms and new therapeutic options that have emerged in thyroid cancer management, potentially impacting clinical practice patterns for endocrinologists and oncologists treating this patient population.
Journal of Clinical Oncology published a reply addressing treatment switching confounds in PHAROS overall survival estimates, per JCO. The methodological discussion highlights ongoing challenges in interpreting survival data when patients cross over to subsequent therapies, a critical issue for regulatory approvals and reimbursement decisions.
Competitive Landscape
Gilead's $5 billion Tubulis acquisition follows a string of ADC deals that have pushed valuations to record levels, according to Fierce Biotech. ADC biotechs command premium valuations Big pharma faces inflated acquisition costs
| Company | ADCs Approved | Pipeline Stage |
|---|---|---|
| Daiichi Sankyo | 3 | Multiple Ph3 |
| AstraZeneca | 2 | 5+ Ph2/3 |
| Gilead (post-deal) | 0 | 1 pivotal-ready |
| Pfizer | 1 | 3 Ph2/3 |
CatalYm's Phase 2b entry targets IO-refractory HCC patients, a growing population with limited second-line options, per PharmaTimes. The GDF-15-targeting approach could differentiate visugromab in a setting where TKI monotherapy remains the default after first-line immunotherapy failure.
EMN24 IsKia trial results could provide Sanofi the clinical edge needed to compete with Janssen's dominant Darzalex franchise, according to Nature Medicine. Four-drug combinations gain momentum Triplet regimens lose market position
MSD's EC approval for Keytruda plus paclitaxel ± bevacizumab in platinum-resistant ovarian cancer creates the first immunotherapy-based option in this EU indication, per Pharmaceutical Technology. With FDA approval already secured in February 2026, MSD now holds a first-mover advantage across major markets for PD-L1-positive patients.
| Regimen | Biomarker | Status |
|---|---|---|
| Keytruda + paclitaxel ± bev | PD-L1 CPS ≥1 | EC Approved |
| Chemotherapy alone | Unselected | Current SOC |
Forward Looking
- Watch for Tubulis ADC pivotal trial initiation timelines and patient enrollment targets to gauge Gilead's accelerated development strategy
- EMN24 IsKia trial readout timing could reshape first-line myeloma treatment standards if four-drug combinations show superior efficacy
- CatalYm's Phase 2b visugromab data in HCC will test whether novel mechanisms can penetrate the checkpoint inhibitor-dominated second-line market
- Additional ADC mega-deals likely as remaining targets like Mersana and ADC Therapeutics become acquisition candidates for Big Pharma
- Keytruda's dual US/EU approval in platinum-resistant ovarian cancer positions MSD to pursue broader ovarian cancer indications; watch for KEYNOTE-B96 long-term OS data and potential label expansion into earlier treatment lines